Loading clinical trials...
Loading clinical trials...
This is a single-center, prospective, open label study in islet transplant recipients following islet graft loss.
After complete islet graft loss is determined, patient's maintenance immunosuppression (i.e. sirolimus, tacrolimus, MMF and/or Myfortic®) will be discontinued and they will be monitored for 10 years thereafter, for the appearance of allosensitization using panel reactive antibody (PRA) levels and monitor the persistence of elevated PRA levels. Primary objective is to determine the rate of allosensitization in patients 3 years after failed islet transplantation (i.e. stimulated c-peptide \<0.3mg/mL) and monitor the persistence of elevated PRA levels (≥ 20%) at year 3, 6, and 9. Timing, frequency and level of change in PRA will be monitored after all immunosuppression is discontinued.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Diabetes Research Institute
Miami, Florida, United States
Start Date
December 1, 2008
Primary Completion Date
December 1, 2027
Completion Date
July 1, 2028
Last Updated
January 27, 2025
60
ESTIMATED participants
Lead Sponsor
Rodolfo Alejandro
NCT07051005
NCT06390371
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03228732